Late stage attritions in drug
discovery are costly and consuming. Improbable response of test molecules
acquired in non-human systems is attributed to be the major cause of clinical
failures. While conventional in vitro methods of drug discovery do not truly represent the human system, the animal models used for in vivo validation are
also genetically and phenotypically distant from humans. However, recent
developments in organoid culture are motivating and elevate hopes for replacing
test animals with artificial human tissue models.
Possibility of creating
functional tissue ex vivo has a potential to revolutionize the way human
therapeutics is perceived. Not only will it bridge the gap between drug development and its clinical efficacy but also help strategizing regenerative medicine. Successful human-tissue surrogates would liberate test animals or at
least minimize their use for research purposes.
No comments:
Post a Comment